MYGN Myriad Genetics, Inc. - Common Stock
Acerca de Myriad Genetics, Inc. - Common Stock Descripción general de la empresa de Wikipedia
Myriad Genetics, Inc. is an American genetic testing and precision medicine company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new products that assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to a particular drug therapy, assess a patient's risk of disease progression and disease recurrence, and measure disease activity.
Leer más
Myriad Genetics, Inc. is an American genetic testing and precision medicine company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new products that assess an individual's risk for developing disease later in life (predictive medicine), identify a patient's likelihood of responding to a particular drug therapy (precision medicine), assess a patient's risk of disease progression and disease recurrence (precision medicine), and measure disease activity.
History
The global search for the genetic basis of breast cancer began when Mary-Claire King, Ph.D., from the University of California, Berkeley announced the localization through linkage analysis of a gene associated with increased risk for breast cancer (BRCA1) to the long arm of chromosome 17.
To further locate the actual gene, Dr. Skolnick and his colleagues invented a gene mapping technique known as Restriction Fragment-length Polymorphisms (RFLP). Gilbert joined Kimberlin in 1991, and they teamed up with Skolnick to form Myriad Genetics.
In August 1994, Mark Skolnick and researchers at Myriad, along with colleagues at the University of Utah, the U.S. National Institutes of Health (NIH), and McGill University sequenced BRCA1. They attempted to patent this gene, which resulted in significant controversy and a landmark Supreme Court Case.
The firm then established the first clinical laboratory to commercialize genomic testing. Myriad created the first test to measure the molecular biology and aggressiveness of men’s prostate cancer, devised a method to assess the inherited breast cancer risk of any woman not previously diagnosed with breast cancer, regardless of ancestry, important for addressing racial and ethnic disparities, commercialized a psychotropic test that covers 61 medications commonly prescribed for depression, anxiety, ADHD. Also pioneering the field of DNA-specific medicine, Myriad received the first FDA approval for a lab-developed diagnostic test for use in predicting the responses to a DNA-repair drug.
Acquisitions and subsidiaries
In August 2016, Myriad announced it would acquire Assurex Health for up to $410 million, expanding the company's genetic testing for psychotropic medicine selection.
In July 2018, Myriad completed an acquisition of reproductive genetic testing firm Counsyl for $375 million, expanding the company's testing capabilities to carrier and prenatal screening.
Other subsidiaries of Myriad Genetics include Myriad International and Myriad Autoimmune (aka Crescendo Bioscience).
Founders
The founders of Myriad are Peter Meldrum (past President and CEO of Agridyne and past CEO and President of Myriad Genetics, Inc.) and Mark Skolnick (Adjunct Professor in the Department of Medical Informatics at the University of Utah).
Products
Among the prognostic tests developed and marketed by Myriad is "Prolaris", which uses gene expression profiling to provide a 10-year prostate cancer-specific risk of death. Another prognostic test, marketed as "myRisk Hereditary Cancer", reviews genetic markers correlated with elevated risk of developing any of eleven hereditary cancers.
Controversies
Myriad Genetics's patents on human genes became quite controversial. Following the discovery by Mary-Claire King that a gene on chromosome 17 is associated with an increased risk of breast cancer, Myriad attempted to patent this gene. These patents were the subject of scrutiny after Myriad became involved in a lawsuit over its patenting practices, which led to the landmark Supreme Court decision Association for Molecular Pathology v. Myriad Genetics, Inc. which ruled these patents illegal. Because genes occur naturally in every human, in addition to raising moral questions, some believe that patents constitute an obstacle to biomedical research worldwide. Additionally, the discovery of their relevance to breast cancer was funded by the public.
Patent lawsuits
In 2010–2013 Myriad Genetics was a defendant in the case Association for Molecular Pathology v. Myriad Genetics (formerly Association For Molecular Pathology et al. v. United States Patent and Trademark Office).
Lawyers at the ACLU served as counsel for the plaintiffs. In the suit, medical associations, doctors, and patients sued Myriad Genetics to challenge seven United States patents on genes related to breast cancer and ovarian cancer.
Two of the company's patents on the BRCA1 and BRCA2 genes, which are inherited gene mutations that link to around half of the 5%–10% of inherited gene mutating breast cancer cases in the US[27], were ruled invalid on March 29, 2010, by Judge Robert W. Sweet in the U.S. District Court for the Southern District of New York. On appeal, the Court of Appeals for the Federal Circuit reversed the trial court in an opinion dated July 29, 2011 and held that the genes were eligible for patents. On December 7, 2011, the ACLU filed a petition for a writ of certiorari to the Supreme Court. On March 26, 2012, the Supreme Court vacated the Federal Circuit's judgment and remanded the case for further consideration in light of Mayo Collaborative Services v. Prometheus Laboratories, Inc., in which the Supreme Court had ruled, just six days earlier, that more restrictive rules were required to patent observations about natural phenomena.
On August 16, 2012, the Federal Circuit reaffirmed Myriad's right to patent the genes (because isolated genes are different from their natural state, using its own precedent in Amgen v. Chugai Pharmaceutical), although they denied patent claims on methods comprising comparison of DNA sequences, as unpatentable "mental acts". On November 30, 2012, the Supreme Court agreed to hear a second challenge to the two gene patents held by Myriad. Oral argument took place on April 15, 2013. On June 13, 2013, in Association for Molecular Pathology v. Myriad Genetics (No. 12-398), the US Supreme Court unanimously ruled that "A naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated", invalidating Myriad's patents on the BRCA1 and BRCA2 genes. However, the Court also held that manipulation of a gene to create something not found in nature—such as a strand of synthetically-produced complementary DNA (cDNA)—could still be eligible for patent protection.
Myriad Genetics has also been involved in litigation in Australia over the patentability of DNA sequences (D'Arcy v Myriad Genetics Inc (2015)). Regarding BRCA1, the company succeeded in the Federal Court, both at first instance and on appeal to the full court, but in October 2015 lost in a unanimous decision of the High Court, D'Arcy v Myriad Genetics Inc.
Fuente: Wikipedia (Inglés), CC BY-SA 4.0 · Ver en Wikipedia ↗
MYGN Instantánea de la Acción Precio, capitalización bursátil, P/E, BPA, ROE, deuda/capital, rango de 52 semanas
MYGN Gráfico del Precio de la Acción OHLCV diario con indicadores técnicos — desplace, amplíe y personalice su vista
Rendimiento a 10 años Tendencias de ingresos, beneficio neto, márgenes y BPA
Valoración Ratios P/E, P/S, P/B, EV/EBITDA: ¿está la acción cara o barata?
Rentabilidad Márgenes brutos, operativos y netos; ROE, ROA, ROIC
Salud financiera Deuda, liquidez, solvencia — solidez del balance general
Crecimiento Crecimiento de ingresos, BPA y beneficio neto: interanual, CAGR a 3 años, CAGR a 5 años
Eficiencia de capital Rotación de activos, rotación de inventario, rotación de cuentas por cobrar
Dividendos Rendimiento, ratio de pago, historial de dividendos, CAGR a 5 años
| Fecha ex-dividendo | Monto |
|---|---|
| 1 de julio de 2009 | $1,7500 |
| 15 de junio de 2009 | $1,7500 |
MYGN Consenso de analistas Opiniones de analistas alcistas y bajistas, precio objetivo a 12 meses, potencial alcista
- Compra fuerte 0 0,0%
- Compra 2 13,3%
- Mantener 8 53,3%
- Venta 2 13,3%
- Venta fuerte 3 20,0%
Precio objetivo a 12 meses
7 analistas · 2026-08-17Historial de Ganancias EPS real vs estimado, sorpresa %, tasa de aciertos, próxima fecha de resultados
| Período | EPS Actual | EPS est. | Sorpresa |
|---|---|---|---|
| 30 de junio de 2026 | $-0.25 | $-0.06 | -0.19% |
| 31 de marzo de 2026 | $-0.09 | $-0.07 | -0.02% |
| 31 de diciembre de 2025 | $0.04 | $-0.01 | 0.05% |
| 30 de septiembre de 2025 | $0.00 | $-0.01 | 0.01% |
| 30 de junio de 2025 | $0.05 | $-0.01 | 0.06% |
| 31 de marzo de 2025 | $-0.03 | $-0.06 | 0.03% |
Comparación de pares (subindustria GICS) Métricas clave frente a competidores del sector
| Ticker | Capitalización Bursátil | P/E | Ingresos interanuales | Margen Neto | ROE | Margen Bruto |
|---|---|---|---|---|---|---|
| MYGN | $575M | -1.6 | -1.6% | -44.4% | -96.8% | 69.9% |
| CAMP | $318M | -2.3 | 436.5% | -2298.5% | -183.4% | — |
| IRD | $140M | -2.5 | 29.1% | -349.3% | -302.2% | — |
| AVXL | $771M | -16.5 | -36.1% | -991.4% | -47.7% | — |
| ELDN | $114M | -2.9 | — | — | -69.4% | — |
| ANIK | $133M | -12.6 | -5.9% | -9.6% | -7.5% | 56.6% |
| TRDA | $394M | -3.0 | -87.9% | -565.5% | -41.9% | — |
| RNAC | $188M | -1.4 | -92.8% | -4658.6% | 202.4% | — |
| SRZN | — | — | — | — | — | — |
| SION | $1.84B | -21.9 | — | — | -23.4% | — |
Fundamentales Completos Todas las métricas por año — estado de resultados, balance general, flujo de caja
Estado de resultados 18
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $824M | $838M | $753M | $678M | $691M | $557M | $851M | $744M | $729M | $740M | $722M | |
| Cost of Revenue | $248M | $252M | $236M | $202M | · | · | · | · | $145M | $133M | $133M | |
| Gross Profit | $577M | $585M | $517M | $476M | · | · | · | · | · | · | · | |
| R&D Expense | $107M | $113M | $89M | $85M | $82M | $73M | $86M | $71M | $74M | $71M | $76M | |
| SG&A Expense | $257M | $276M | $284M | $248M | $538M | $497M | $557M | $435M | $440M | $359M | $366M | |
| Operating Expenses | $964M | $709M | $774M | $617M | $881M | $847M | $844M | $622M | $685M | $587M | $589M | |
| Operating Income | $-387M | $-124M | $-257M | $-141M | $-190M | $-290M | $8M | $122M | $44M | $153M | $134M | |
| Interest Expense | · | · | $3M | $3M | $7M | $11M | $12M | $3M | $6M | $300.0K | $200.0K | |
| Interest Income | $2M | $2M | $2M | $3M | $700.0K | $2M | $3M | $2M | $1M | $900.0K | $400.0K | |
| Other Non-op | $800.0K | $1M | $-4M | $600.0K | $139M | $15M | $1M | $-400.0K | $-3M | $2M | $500.0K | |
| Pretax Income | $-395M | $-124M | $-262M | $-141M | $-57M | $-284M | $0 | $120M | $36M | $156M | $134M | |
| Income Tax | $-29M | $4M | $1M | $-29M | $-30M | $-60M | $-4M | $-13M | $19M | $39M | $54M | |
| Net Income | $-366M | $-127M | $-263M | $-112M | $-27M | $-224M | $5M | $133M | $17M | $117M | $80M | |
| EPS (Basic) | $-3.95 | $-1.41 | $-3.18 | $-1.39 | $-0.35 | $-2.99 | $0.06 | $1.92 | $0.25 | $1.67 | $1.12 | |
| EPS (Diluted) | $-3.95 | $-1.41 | $-3.18 | $-1.39 | $-0.35 | $-2.99 | $0.06 | $1.85 | $0.25 | $1.60 | $1.07 | |
| Shares (Basic) | 92,600,000 | 90,600,000 | 82,800,000 | 80,600,000 | 78,000,000 | 74,800,000 | 73,500,000 | 69,400,000 | 68,300,000 | 70,000,000 | 71,300,000 | |
| Shares (Diluted) | 92,600,000 | 90,600,000 | 82,800,000 | 80,600,000 | 78,000,000 | 74,800,000 | 76,000,000 | 72,000,000 | 68,800,000 | 73,400,000 | 74,500,000 | |
| EBITDA | $-387M | $-124M | $-257M | $-141M | $-190M | · | $8M | $119M | $49M | $167M | · |
Balance general 29
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $150M | $102M | $132M | $57M | $257M | $117M | $93M | $111M | $102M | $68M | $64M | |
| Short-term Investments | · | $0 | $9M | $58M | $81M | $34M | $44M | $70M | $48M | $90M | $81M | |
| Receivables | $115M | $121M | $114M | $102M | $91M | $90M | $134M | $100M | $89M | $92M | $86M | |
| Inventory | $31M | $28M | $22M | $20M | $15M | $27M | $31M | $34M | $42M | $38M | $25M | |
| Prepaid Expense | $25M | $30M | $19M | $20M | $21M | $14M | · | · | · | · | · | |
| Current Assets | $333M | $298M | $314M | $275M | $485M | $389M | $349M | $328M | $302M | $314M | $284M | |
| PP&E (Net) | $114M | $117M | $119M | $83M | $44M | $41M | $57M | $43M | $51M | $58M | $67M | |
| PP&E (Gross) | $202M | $227M | $239M | $193M | $150M | $154M | $169M | $157M | $148M | $142M | $138M | |
| Accum. Depreciation | $88M | $110M | $120M | $109M | $107M | $113M | $112M | $114M | $97M | $83M | $71M | |
| Goodwill | $52M | $286M | $287M | $287M | $239M | $329M | $417M | $319M | $316M | $195M | $177M | |
| Intangibles | $153M | $262M | $350M | $380M | $404M | $576M | $685M | $455M | $492M | $228M | $193M | |
| Other Non-current Assets | $6M | $8M | $15M | $16M | $8M | $2M | · | · | · | $5M | $5M | |
| Total Assets | $707M | $1.03B | $1.15B | $1.20B | $1.32B | $1.42B | $1.56B | $1.18B | $1.21B | $880M | $766M | |
| Accounts Payable | $30M | $32M | $26M | $29M | $30M | $20M | $33M | $26M | $22M | $21M | $21M | |
| Accrued Liabilities | $97M | $119M | $114M | $94M | $162M | $79M | $79M | $68M | $66M | $50M | $46M | |
| Current Liabilities | $134M | $164M | $156M | $137M | $204M | $146M | $118M | $102M | $218M | $72M | $69M | |
| Capital Leases | $83M | $88M | $97M | $131M | $79M | $51M | · | · | · | · | · | |
| Deferred Tax | · | · | · | $4M | $36M | $71M | $83M | $57M | $79M | $18M | $200.0K | |
| Other Non-current Liabilities | $2M | $2M | $41M | $18M | $6M | $15M | $8M | $6M | $7M | $8M | $4M | |
| Total Liabilities | $339M | $326M | $363M | $313M | $353M | $538M | $474M | $209M | $441M | $132M | $104M | |
| Long-term Debt | $120M | $40M | · | $0 | $0 | $225M | $234M | $9M | $99M | · | · | |
| Total Debt | $120M | $40M | $38M | · | $0 | · | $234M | $9M | · | · | · | |
| Common Stock | $900.0K | $900.0K | $900.0K | $800.0K | $800.0K | $800.0K | $700.0K | $700.0K | $700.0K | $700.0K | $700.0K | |
| Paid-in Capital | · | · | · | · | · | · | · | · | · | · | $745M | |
| Retained Earnings | $-1.12B | $-757M | $-630M | $-366M | $-254M | $-227M | $26M | $54M | $-79M | $-73M | $-77M | |
| AOCI | $800.0K | $-800.0K | $-4M | $-9M | $-5M | $-2M | $-5M | $-4M | $-6M | $-10M | $-7M | |
| Stockholders' Equity | $368M | $701M | $783M | $886M | $968M | $881M | $1.09B | $966M | $768M | $740M | $662M | |
| Liabilities + Equity | $707M | $1.03B | $1.15B | $1.20B | $1.32B | $1.42B | $1.56B | $1.18B | $1.21B | $880M | $766M | |
| Shares Outstanding | 93,500,000 | 91,300,000 | 89,900,000 | 81,200,000 | 80,000,000 | 75,400,000 | 73,500,000 | 70,600,000 | 68,400,000 | 69,100,000 | 68,900,000 |
Flujo de Efectivo 13
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $54M | $61M | $62M | $53M | $63M | · | $73M | $54M | $48M | $27M | $25M | |
| Stock-based Comp | $35M | $50M | $41M | $38M | $36M | · | $34M | $27M | $30M | $32M | $46M | |
| Deferred Tax | $1M | $-2M | $-4M | $-30M | $-32M | · | $20M | $-23M | $1M | $13M | $-4M | |
| Amort. of Intangibles | $35M | $42M | $43M | $41M | $51M | · | $59M | $37M | $33M | $13M | $13M | |
| Operating Cash Flow | $2M | $-9M | $-111M | $-106M | $19M | · | $84M | $116M | $106M | $166M | $140M | |
| CapEx | · | · | · | $45M | $18M | · | $9M | $8M | $6M | $5M | $24M | |
| Investing Cash Flow | $-27M | $-12M | $32M | $-78M | $274M | · | $-286M | $-12M | $-146M | $-91M | · | |
| Stock Repurchased | · | · | · | · | $0 | · | $50M | · | $32M | $163M | $211M | |
| Net Stock Activity | · | · | · | · | $0 | · | $-50M | · | $-32M | $-163M | · | |
| Financing Cash Flow | $64M | $-7M | $153M | $-8M | $-151M | · | $182M | $-95M | $72M | $-68M | · | |
| Net Change in Cash | $39M | $-29M | $74M | $-192M | $142M | · | $-18M | $8M | $34M | $4M | $-700.0K | |
| Free Cash Flow | · | · | · | $-152M | $200.0K | · | $75M | $108M | $100M | $161M | · | |
| Levered FCF | · | · | · | $-154M | $-3M | · | · | $104M | $97M | · | · |
Rentabilidad 8
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 69.9% | 69.9% | · | · | · | · | · | · | · | · | · | |
| Operating Margin | -47.0% | -14.7% | -34.2% | -20.7% | -27.6% | · | 0.89% | 15.4% | 6.4% | 22.1% | · | |
| Net Margin | -44.4% | -15.2% | -35.0% | -16.5% | -3.9% | · | 0.54% | 17.0% | 2.8% | 16.6% | · | |
| Pretax Margin | -47.9% | -14.7% | -34.8% | -20.7% | -8.3% | · | 0.00% | 15.1% | 5.6% | 22.4% | · | |
| EBITDA Margin | -47.0% | -14.7% | -34.2% | -20.7% | -27.6% | · | 0.89% | 15.4% | 6.4% | 22.1% | · | |
| ROA | -42.2% | -11.7% | -22.4% | -8.9% | -2.0% | · | 0.34% | 11.0% | 2.1% | 15.2% | · | |
| ROE | -96.8% | -17.8% | -35.9% | -12.4% | -2.9% | · | 0.42% | 15.1% | 2.9% | 17.8% | · | |
| ROIC | -73.5% | -17.2% | -31.5% | -12.6% | -9.4% | · | · | 13.6% | 3.2% | 16.5% | · |
Liquidez y Solvencia 5
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.5 | 1.8 | 2.0 | 2.0 | 2.4 | · | 3.0 | 3.2 | 1.5 | 4.3 | · | |
| Quick Ratio | 2.0 | 1.4 | 1.6 | 1.6 | 2.1 | · | 2.3 | 2.7 | 1.2 | 3.5 | · | |
| Debt / Equity | 0.3 | 0.1 | 0.0 | · | 0.0 | · | 0.2 | 0.0 | · | · | · | |
| LT Debt / Equity | 0.3 | 0.1 | 0.0 | · | 0.0 | · | 0.2 | 0.0 | · | · | · | |
| Interest Coverage | · | · | -88.8 | -43.9 | -28.9 | · | 0.6 | 37.1 | 8.2 | · | · |
Eficiencia 3
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 1.0 | 0.8 | 0.6 | 0.5 | 0.5 | · | 0.6 | 0.6 | 0.7 | 0.9 | · | |
| Inventory Turnover | 8.5 | 10.2 | · | · | · | · | · | · | 3.6 | 4.2 | · | |
| Receivables Turnover | 7.0 | 7.1 | 7.0 | 7.0 | 7.6 | · | 7.3 | 8.2 | 7.8 | 8.5 | · |
Tasas de Crecimiento 3
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -1.6% | 11.2% | 11.0% | -1.8% | 24.0% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 6.7% | 6.6% | 10.6% | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 8.2% | · | · | · | · | · | · | · | · | · | · |
Valoración (TTM) 14
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $824M | $838M | $753M | $678M | $691M | · | $851M | $744M | $729M | $740M | $722M | |
| Net Income TTM | $-366M | $-127M | $-263M | $-112M | $-27M | · | $5M | $133M | $17M | $117M | $80M | |
| Market Cap | $575M | $1.25B | $1.72B | $1.18B | $2.21B | · | $2.04B | $2.64B | $1.77B | $2.11B | · | |
| Enterprise Value | $545M | $1.19B | $1.62B | · | $1.87B | · | $2.14B | $2.47B | · | · | · | |
| P/E | -1.6 | -9.7 | -6.0 | -10.4 | -78.9 | · | 463.0 | 20.2 | 103.4 | 19.1 | 31.8 | |
| P/S | 0.7 | 1.5 | 2.3 | 1.7 | 3.2 | · | 2.4 | 3.5 | 2.4 | 2.9 | · | |
| P/B | 1.6 | 1.8 | 2.2 | 1.3 | 2.3 | · | 1.9 | 2.7 | 2.3 | 2.8 | · | |
| P / Tangible Book | 3.5 | 8.2 | 11.8 | 5.4 | 6.8 | · | · | · | · | · | · | |
| P / Cash Flow | 319.5 | -143.9 | -15.5 | -11.1 | 121.3 | · | 24.4 | 22.8 | 16.6 | 12.7 | · | |
| P / FCF | · | · | · | -7.8 | 11040.0 | · | 27.2 | 24.5 | 17.7 | 13.1 | · | |
| EV / EBITDA | -1.4 | -9.6 | -6.3 | · | -9.8 | · | 281.4 | 20.8 | · | · | · | |
| EV / FCF | · | · | · | · | 9341.0 | · | 28.5 | 22.9 | · | · | · | |
| EV / Revenue | 0.7 | 1.4 | 2.1 | · | 2.7 | · | 2.5 | 3.3 | · | · | · | |
| Earnings Yield | -64.2% | -10.3% | -16.6% | -9.6% | -1.3% | · | 0.22% | 5.0% | 0.97% | 5.2% | 3.1% |
Estado de resultados 18
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $191M | $200M | $210M | $206M | $213M | $196M | $211M | $213M | $212M | $202M | $197M | $192M | $184M | $181M | $178M | $156M | |
| Cost of Revenue | $64M | $63M | $63M | $62M | $61M | $62M | $60M | $64M | $64M | $65M | $62M | $58M | $58M | $59M | $54M | $50M | |
| Gross Profit | $127M | $138M | $147M | $144M | $152M | $134M | $151M | $150M | $147M | $138M | · | · | · | · | · | · | |
| R&D Expense | $25M | $27M | $26M | $28M | $26M | $28M | $33M | $28M | $27M | $25M | $21M | $24M | $21M | $22M | $23M | $20M | |
| SG&A Expense | $58M | $62M | $56M | $68M | $67M | $66M | $63M | $69M | $72M | $71M | $-145M | $136M | $141M | $152M | $-120M | $130M | |
| Operating Expenses | $166M | $168M | $152M | $167M | $481M | $163M | $190M | $170M | $184M | $166M | $-8M | $252M | $297M | $233M | $28M | $201M | |
| Operating Income | $-39M | $-31M | $-6M | $-23M | $-329M | $-29M | $-39M | $-20M | $-36M | $-28M | $-31M | $-60M | $-114M | $-52M | $-52M | $-45M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $500.0K | · | $1M | $500.0K | $500.0K | · | $800.0K | |
| Interest Income | $400.0K | $700.0K | $800.0K | $500.0K | $200.0K | $300.0K | $300.0K | $400.0K | $400.0K | $600.0K | $700.0K | $600.0K | $500.0K | $700.0K | $1M | $1M | |
| Other Non-op | $0 | $0 | $400.0K | $400.0K | $-100.0K | $100.0K | $300.0K | $-800.0K | $-300.0K | $2M | $-700.0K | $-700.0K | $-2M | $-600.0K | $0 | $500.0K | |
| Pretax Income | $-43M | $-34M | $-9M | $-26M | $-331M | $-29M | $-39M | $-21M | $-37M | $-26M | $-32M | $-61M | $-116M | $-53M | $-52M | $-44M | |
| Income Tax | $600.0K | $0 | $-1M | $1M | $-100.0K | $-29M | $3M | $900.0K | $-500.0K | $100.0K | $-1M | $100.0K | $0 | $2M | $-10M | $-9M | |
| Net Income | $-43M | $-34M | $-8M | $-27M | $-330M | $-100.0K | $-42M | $-22M | $-37M | $-26M | $-31M | $-61M | $-116M | $-55M | $-42M | $-35M | |
| EPS (Basic) | $-0.46 | $-0.36 | $-0.09 | $-0.29 | $-3.57 | $0.00 | $-0.47 | $-0.24 | $-0.41 | $-0.29 | $-0.34 | $-0.75 | $-1.42 | $-0.67 | $-0.52 | $-0.43 | |
| EPS (Diluted) | $-0.46 | $-0.36 | $-0.09 | $-0.29 | $-3.57 | $0.00 | $-0.47 | $-0.24 | $-0.41 | $-0.29 | $-0.34 | $-0.75 | $-1.42 | $-0.67 | $-0.52 | $-0.43 | |
| Shares (Basic) | 94,800,000 | 93,700,000 | -184,400,000 | 93,100,000 | 92,500,000 | 91,400,000 | -180,800,000 | 90,900,000 | 90,600,000 | 89,900,000 | -162,100,000 | 81,900,000 | 81,700,000 | 81,300,000 | -160,600,000 | 80,700,000 | |
| Shares (Diluted) | 94,800,000 | 93,700,000 | -184,400,000 | 93,100,000 | 92,500,000 | 91,400,000 | -180,800,000 | 90,900,000 | 90,600,000 | 89,900,000 | -162,100,000 | 81,900,000 | 81,700,000 | 81,300,000 | -160,600,000 | 80,700,000 | |
| EBITDA | $-39M | $-31M | · | $-23M | $-329M | $-29M | · | $-20M | $-36M | $-28M | · | $-60M | $-114M | $-52M | · | $-45M |
Balance general 28
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $115M | $124M | $150M | $145M | $74M | $92M | $102M | $100M | $92M | $97M | $132M | $76M | $103M | $54M | $57M | $111M | |
| Short-term Investments | · | · | · | · | · | · | · | $0 | $5M | $7M | · | $10M | $19M | $25M | · | $82M | |
| Receivables | $110M | $124M | $115M | $118M | $137M | $120M | $121M | $126M | $118M | $118M | · | $115M | $112M | $119M | · | $102M | |
| Inventory | $31M | $28M | $31M | $32M | $29M | $28M | $28M | $26M | $26M | $25M | · | $25M | $22M | $22M | · | $20M | |
| Prepaid Expense | $32M | $35M | $25M | $36M | $30M | $32M | $30M | $24M | $22M | $25M | · | $21M | $21M | $24M | · | $20M | |
| Current Assets | $289M | $313M | $333M | $345M | $284M | $287M | $298M | $293M | $292M | $290M | · | $265M | $294M | $262M | · | $352M | |
| PP&E (Net) | $109M | $112M | $114M | $111M | $113M | $114M | $117M | $115M | $116M | $118M | · | $121M | $112M | $96M | · | $68M | |
| PP&E (Gross) | $201M | $202M | $202M | $195M | $192M | $198M | $227M | $233M | $231M | $229M | · | $239M | $227M | $208M | · | $176M | |
| Accum. Depreciation | $92M | $90M | $88M | $83M | $79M | $84M | $110M | $117M | $114M | $111M | · | $118M | $115M | $112M | · | $108M | |
| Goodwill | $47M | $47M | $52M | $52M | $52M | $286M | $286M | $286M | $286M | $287M | · | $287M | $287M | $287M | · | $236M | |
| Intangibles | $139M | $146M | $153M | $163M | $170M | $258M | $262M | $312M | $320M | $341M | · | $357M | $359M | $369M | · | $371M | |
| Other Non-current Assets | $5M | $6M | $6M | $7M | $7M | $8M | $8M | $16M | $15M | $15M | · | $16M | $22M | $18M | · | $8M | |
| Total Assets | $639M | $674M | $707M | $728M | $677M | $1.01B | $1.03B | $1.08B | $1.09B | $1.11B | · | $1.15B | $1.19B | $1.17B | · | $1.21B | |
| Accounts Payable | $30M | $33M | $30M | $32M | $31M | $28M | $32M | $30M | $33M | $33M | · | $34M | $40M | $36M | · | $30M | |
| Accrued Liabilities | $93M | $90M | $97M | $108M | $101M | $112M | $119M | $111M | $98M | $99M | · | $158M | $164M | $92M | · | $85M | |
| Current Liabilities | $131M | $130M | $134M | $148M | $200M | $151M | $164M | $154M | $149M | $146M | · | $209M | $221M | $143M | · | $129M | |
| Capital Leases | $82M | $84M | $83M | $85M | $86M | $87M | $88M | $91M | $91M | $94M | · | $145M | $148M | $146M | · | $123M | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | · | · | $3M | $4M | $4M | · | $10M | |
| Other Non-current Liabilities | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $34M | $35M | $41M | · | $40M | $11M | $12M | · | $5M | |
| Total Liabilities | $335M | $336M | $339M | $355M | $289M | $301M | $326M | $350M | $345M | $350M | · | $466M | $452M | $334M | · | $295M | |
| Long-term Debt | $121M | $120M | $120M | $120M | $59M | · | · | · | · | · | · | · | · | $0 | · | $0 | |
| Total Debt | $121M | $120M | · | $120M | $59M | $59M | · | $39M | $39M | $39M | · | $38M | $38M | · | · | · | |
| Common Stock | $1M | $900.0K | $900.0K | $900.0K | $900.0K | $900.0K | $900.0K | $900.0K | $900.0K | $900.0K | · | $800.0K | $800.0K | $800.0K | · | $800.0K | |
| Retained Earnings | $-1.20B | $-1.16B | $-1.12B | $-1.11B | $-1.09B | $-757M | $-757M | $-714M | $-692M | $-656M | · | $-598M | $-537M | $-421M | · | $-324M | |
| AOCI | $800.0K | $700.0K | $800.0K | $-100.0K | $-100.0K | $-600.0K | $-800.0K | $-100.0K | $-4M | $-4M | · | $-5M | $-5M | $-7M | · | $-11M | |
| Stockholders' Equity | $304M | $337M | $368M | $373M | $388M | $705M | $701M | $732M | $740M | $760M | $783M | $683M | $735M | $835M | $886M | $917M | |
| Liabilities + Equity | $639M | $674M | $707M | $728M | $677M | $1.01B | $1.03B | $1.08B | $1.09B | $1.11B | · | $1.15B | $1.19B | $1.17B | · | $1.21B | |
| Shares Outstanding | 95,600,000 | 94,400,000 | 93,500,000 | 93,100,000 | 93,100,000 | 92,200,000 | 91,300,000 | 91,000,000 | 90,900,000 | 90,500,000 | 89,900,000 | 82,100,000 | 81,900,000 | 81,500,000 | 81,200,000 | 80,900,000 |
Flujo de Efectivo 11
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $12M | $12M | $13M | $13M | $14M | $14M | $15M | $16M | $15M | $16M | $15M | $14M | $13M | $19M | $14M | $13M | |
| Stock-based Comp | $7M | $6M | $3M | $12M | $11M | $10M | $11M | $12M | $14M | $12M | $10M | $12M | $11M | $8M | $8M | $9M | |
| Amort. of Intangibles | $8M | $8M | $8M | $8M | $9M | $9M | $10M | $10M | $11M | $11M | $11M | $11M | $11M | $11M | $10M | $10M | |
| Operating Cash Flow | $-8M | $-16M | $11M | $21M | $-14M | $-16M | $7M | $700.0K | $3M | $-19M | $-55M | $-22M | $-900.0K | $-33M | $-7M | $-2M | |
| CapEx | · | · | · | · | · | · | · | · | · | · | · | · | $19M | $24M | · | $18M | |
| Investing Cash Flow | $-3M | $-6M | $-6M | $-6M | $-7M | $-8M | $-6M | $8M | $-6M | $-7M | $-12M | $-2M | $12M | $35M | $-36M | $11M | |
| Financing Cash Flow | $2M | $-3M | $-8M | $56M | $3M | $14M | $2M | $-3M | $2M | $-9M | $122M | $-2M | $38M | $-5M | $-2M | $-4M | |
| Net Change in Cash | $-9M | $-25M | $-4M | $71M | $-17M | $-11M | $2M | $9M | $-4M | $-35M | $56M | $-28M | $50M | $-3M | $-44M | $5M | |
| Taxes Paid | $400.0K | $-12M | · | · | $0 | $300.0K | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | · | · | · | · | $-57M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | · | · | · | · | $-57M | · | · |
Rentabilidad 8
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 66.6% | 68.7% | · | 69.9% | 71.2% | 68.5% | · | · | · | · | · | · | · | · | · | · | |
| Operating Margin | -20.4% | -15.3% | · | -11.3% | -154.5% | -14.8% | · | -9.4% | -17.3% | -13.8% | · | -31.3% | -62.0% | -28.8% | · | -28.8% | |
| Net Margin | -22.7% | -17.0% | · | -13.3% | -155.1% | -0.05% | · | -10.4% | -17.3% | -12.9% | · | -31.9% | -63.3% | -30.2% | · | -22.4% | |
| Pretax Margin | -22.3% | -17.0% | · | -12.7% | -155.1% | -15.0% | · | -9.9% | -17.6% | -12.8% | · | -31.9% | -63.3% | -29.0% | · | -28.3% | |
| EBITDA Margin | -20.4% | -15.3% | · | -11.3% | -154.5% | -14.8% | · | -9.4% | -17.3% | -13.8% | · | -31.3% | -62.0% | -28.8% | · | -28.8% | |
| ROA | -6.6% | -4.1% | · | -3.0% | -37.5% | -0.01% | · | -2.0% | -3.2% | -2.3% | · | -5.2% | -9.7% | -4.5% | · | -2.8% | |
| ROE | -12.5% | -6.5% | · | -5.0% | -58.6% | -0.01% | · | -3.1% | -5.0% | -3.3% | · | -7.7% | -13.8% | -6.1% | · | -3.7% | |
| ROIC | -9.3% | -6.7% | · | -5.0% | -73.5% | -0.01% | · | -2.7% | -4.6% | -3.5% | · | -8.3% | -14.7% | -6.5% | · | -3.9% |
Liquidez y Solvencia 5
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.2 | 2.4 | · | 2.3 | 1.4 | 1.9 | · | 1.9 | 2.0 | 2.0 | · | 1.3 | 1.3 | 1.8 | · | 2.7 | |
| Quick Ratio | 1.7 | 1.9 | · | 1.8 | 1.1 | 1.4 | · | 1.5 | 1.4 | 1.5 | · | 1.0 | 1.1 | 1.4 | · | 2.3 | |
| Debt / Equity | 0.4 | 0.4 | · | 0.3 | 0.2 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | · | · | · | |
| LT Debt / Equity | 0.4 | 0.4 | · | 0.3 | 0.0 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | · | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | -55.8 | · | -60.1 | -227.4 | -104.4 | · | -56.2 |
Eficiencia 3
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.1 | · | 0.1 | |
| Inventory Turnover | 2.1 | 2.2 | · | 2.1 | 2.2 | 2.3 | · | 2.5 | 2.7 | 2.8 | · | 2.6 | 3.1 | 3.2 | · | · | |
| Receivables Turnover | 1.5 | 1.6 | · | 1.7 | 1.7 | 1.6 | · | 1.8 | 1.8 | 1.7 | · | 1.8 | 1.7 | 1.6 | · | 1.6 |
Valoración (TTM) 13
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $810M | $815M | · | $828M | $834M | $823M | · | $819M | $789M | $759M | · | $713M | $700M | $682M | · | $668M | |
| Net Income TTM | $-435M | $-392M | · | $-380M | $-389M | $-85M | · | $-146M | $-240M | $-258M | · | $-267M | $-220M | $-124M | · | $-45M | |
| Market Cap | $546M | $425M | · | $673M | $494M | $818M | · | $2.49B | $2.22B | $1.93B | · | $1.32B | $1.90B | $1.89B | · | $1.54B | |
| Enterprise Value | $551M | $421M | · | $647M | $479M | $785M | · | $2.43B | $2.16B | $1.86B | · | $1.27B | $1.82B | · | · | · | |
| P/E | -1.2 | -1.1 | · | -1.8 | -1.3 | -9.4 | · | -16.2 | -8.5 | -6.8 | · | -4.9 | -8.6 | -15.1 | · | -33.5 | |
| P/S | 0.7 | 0.5 | · | 0.8 | 0.6 | 1.0 | · | 3.0 | 2.8 | 2.5 | · | 1.8 | 2.7 | 2.8 | · | 2.3 | |
| P/B | 1.8 | 1.3 | · | 1.8 | 1.3 | 1.2 | · | 3.4 | 3.0 | 2.5 | · | 1.9 | 2.6 | 2.3 | · | 1.7 | |
| P / Tangible Book | 4.6 | 2.9 | · | 4.3 | 3.0 | 5.1 | · | 18.8 | 16.5 | 14.6 | · | 32.8 | 21.3 | 10.6 | · | 5.0 | |
| P / Cash Flow | · | -27.1 | · | · | · | -50.2 | · | · | · | -103.7 | · | · | · | -57.0 | · | · | |
| P / FCF | · | · | · | · | · | · | · | · | · | · | · | · | · | -33.4 | · | · | |
| EV / EBITDA | -14.2 | -13.7 | · | -27.8 | -1.5 | -27.1 | · | -121.6 | -59.3 | -66.8 | · | -21.1 | -16.0 | · | · | · | |
| EV / Revenue | 0.7 | 0.5 | · | 0.8 | 0.6 | 1.0 | · | 3.0 | 2.7 | 2.5 | · | 1.8 | 2.6 | · | · | · | |
| Earnings Yield | -82.0% | -93.8% | · | -56.7% | -79.5% | -10.6% | · | -6.2% | -11.7% | -14.7% | · | -20.4% | -11.7% | -6.6% | · | -3.0% |
Estados Financieros Estado de resultados, balance general, flujo de caja — anual, últimos 5 años
Estado de resultados
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Ingresos | $824M | $838M | $753M | $678M | $691M |
| Margen Bruto % | 69.9% | 69.9% | — | — | — |
| Margen Operativo % | -47.0% | -14.7% | -34.2% | -20.7% | -27.6% |
| Beneficio neto | $-366M | $-127M | $-263M | $-112M | $-27M |
| EPS Diluido | $-3.95 | $-1.41 | $-3.18 | $-1.39 | $-0.35 |
Balance general
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Deuda / Patrimonio | 0.3 | 0.1 | 0.0 | — | 0.0 |
| Ratio corriente | 2.5 | 1.8 | 2.0 | 2.0 | 2.4 |
| Ratio Rápido | 2.0 | 1.4 | 1.6 | 1.6 | 2.1 |
Flujo de Efectivo
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Flujo de caja libre | — | — | — | $-152M | $200.0K |
Últimas noticias Noticias recientes que mencionan a esta empresa
Mis Métricas Tu lista de seguimiento personal — filas seleccionadas de Fundamentales Completos
Elige las métricas que te importan — haz clic en el ➕ junto a cualquier fila en Fundamentales Completos arriba.
Tu selección se guarda y te sigue en todos los tickers.
Propietarios institucionales (13F) 219 declarantes · $345.6M total · A fecha de 30 de junio de 2026
Instituciones que informan tener esta acción en su Formulario 13F trimestral de la SEC. Solo posiciones largas; un solo presentador puede aparecer dos veces para tramos de opciones separados. Las patas de put/call de compensación grandes suelen reflejar la creación de mercado o el inventario cubierto, no la convicción direccional.
| Nuevas posiciones | Posiciones cerradas | Aumentado | Disminuido | Cambio neto de acciones |
|---|---|---|---|---|
| 52 (+23 vs trimestre anterior) | 42 (-4 vs trimestre anterior) | 65 (-5 vs trimestre anterior) | 56 (-6 vs trimestre anterior) | -116.7M |
Comparado con Q1 2026. Las presentaciones del Formulario 13F de la SEC vencen dentro de los 45 días posteriores al final del trimestre, más un pequeño margen para los presentadores tardíos; los trimestres que aún se encuentran dentro de esa ventana se omiten en favor del par más reciente completamente reportado.
| Institución | Valor | Acciones | % de 13F rastreadas | Tipo |
|---|---|---|---|---|
| MILLENNIUM MANAGEMENT LLC | $37 802 324 | 6 620 372 | 10,94% | Acciones |
| Vestal Point Capital, LP | $32 746 850 | 5 735 000 | 9,48% | Acciones |
| STATE STREET CORP | $28 464 693 | 4 985 060 | 8,24% | Acciones |
| VANGUARD CAPITAL MANAGEMENT LLC | $23 304 657 | 4 081 376 | 6,74% | Acciones |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $17 584 916 | 3 079 670 | 5,09% | Acciones |
| GEODE CAPITAL MANAGEMENT, LLC | $11 816 625 | 2 068 833 | 3,42% | Acciones |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $10 800 619 | 1 891 527 | 3,13% | Acciones |
| Camber Capital Management LP | $10 620 000 | 2 000 000 | 3,07% | Acciones |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $9 939 934 | 1 740 794 | 2,88% | Acciones |
| Qube Research & Technologies Ltd | $9 511 918 | 1 665 835 | 2,75% | Acciones |
| TWO SIGMA INVESTMENTS, LP | $8 894 621 | 1 557 727 | 2,57% | Acciones |
| MACKENZIE FINANCIAL CORP | $8 768 858 | 1 535 702 | 2,54% | Acciones |
| Connor, Clark & Lunn Investment Management Ltd. | $8 012 306 | 1 403 206 | 2,32% | Acciones |
| Aberdeen Group plc | $7 474 007 | 1 308 933 | 2,16% | Acciones |
| CITADEL ADVISORS LLC | $6 482 323 | 1 135 258 | 1,88% | Acciones |
| D. E. Shaw & Co., Inc. | $6 107 827 | 1 069 672 | 1,77% | Acciones |
| GOLDMAN SACHS GROUP INC | $5 962 085 | 1 044 148 | 1,73% | Acciones |
| Assenagon Asset Management S.A. | $5 889 659 | 1 031 464 | 1,70% | Acciones |
| DIMENSIONAL FUND ADVISORS LP | $5 272 317 | 923 348 | 1,53% | Acciones |
| Man Group plc | $5 188 865 | 908 733 | 1,50% | Acciones |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $4 469 588 | 782 765 | 1,29% | Acciones |
| FMR LLC | $4 398 921 | 770 389 | 1,27% | Acciones |
| BANK OF AMERICA CORP /DE/ | $4 232 618 | 741 264 | 1,22% | Acciones |
| Cubist Systematic Strategies, LLC | $3 840 296 | 531 161 | 1,11% | Acciones |
| VANGUARD GROUP INC | $3 620 327 | 588 671 | 1,05% | Acciones |
| VANGUARD FIDUCIARY TRUST CO | $3 555 172 | 622 622 | 1,03% | Acciones |
| AMH Equity Ltd | $2 892 000 | 400 000 | 0,84% | Acciones |
| PRUDENTIAL FINANCIAL INC | $2 819 958 | 493 863 | 0,82% | Acciones |
| Walleye Capital LLC | $2 653 134 | 464 647 | 0,77% | Acciones |
| BNP PARIBAS FINANCIAL MARKETS | $2 567 998 | 449 737 | 0,74% | Acciones |
| OP Asset Management Ltd | $2 567 313 | 449 617 | 0,74% | Acciones |
| BlackRock, Inc. | $2 498 850 | 437 627 | 0,72% | Acciones |
| STATE OF WISCONSIN INVESTMENT BOARD | $2 341 831 | 410 128 | 0,68% | Acciones |
| Squarepoint Ops LLC | $2 190 921 | 383 699 | 0,63% | Acciones |
| TWO SIGMA ADVISERS, LP | $2 092 230 | 340 200 | 0,61% | Acciones |
| Militia Capital Management LLC | $1 720 994 | 301 400 | 0,50% | Acciones |
| AMERIPRISE FINANCIAL INC | $1 488 677 | 260 714 | 0,43% | Acciones |
| Point72 Asset Management, L.P. | $1 363 411 | 238 776 | 0,39% | Acciones |
| XTX Topco Ltd | $1 353 407 | 237 024 | 0,39% | Acciones |
| Jain Global LLC | $1 305 072 | 228 559 | 0,38% | Acciones |
| ExodusPoint Capital Management, LP | $1 211 542 | 212 179 | 0,35% | Acciones |
| Voleon Capital Management LP | $1 209 132 | 211 757 | 0,35% | Acciones |
| PANAGORA ASSET MANAGEMENT INC | $1 169 671 | 204 846 | 0,34% | Acciones |
| MOORE CAPITAL MANAGEMENT, LP | $1 076 483 | 188 526 | 0,31% | Acciones |
| Vanguard Global Advisers, LLC | $1 027 332 | 179 918 | 0,30% | Acciones |
| MARTINGALE ASSET MANAGEMENT L P | $1 019 498 | 178 546 | 0,30% | Acciones |
| Bank of New York Mellon Corp | $939 917 | 164 609 | 0,27% | Acciones |
| FEDERATED HERMES, INC. | $932 831 | 163 368 | 0,27% | Acciones |
| VOYA INVESTMENT MANAGEMENT LLC | $842 648 | 147 574 | 0,24% | Acciones |
| CANADA PENSION PLAN INVESTMENT BOARD | $790 264 | 138 400 | 0,23% | Acciones |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $781 453 | 136 857 | 0,23% | Acciones |
| PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO | $756 969 | 132 569 | 0,22% | Acciones |
| Engineers Gate Manager LP | $712 431 | 124 769 | 0,21% | Acciones |
| RHUMBLINE ADVISERS | $687 490 | 120 403 | 0,20% | Acciones |
| CITIGROUP INC | $636 562 | 111 482 | 0,18% | Acciones |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | $630 190 | 110 366 | 0,18% | Acciones |
| State of Wyoming | $615 441 | 107 783 | 0,18% | Acciones |
| Mariner, LLC | $555 463 | 97 276 | 0,16% | Acciones |
| DEUTSCHE BANK AG\ | $515 253 | 90 237 | 0,15% | Acciones |
| AMERICAN CENTURY COMPANIES INC | $490 301 | 85 867 | 0,14% | Acciones |
| Rafferty Asset Management, LLC | $478 618 | 83 821 | 0,14% | Acciones |
| ZACKS INVESTMENT MANAGEMENT | $464 749 | 81 392 | 0,13% | Acciones |
| ALLIANCEBERNSTEIN L.P. | $436 838 | 97 075 | 0,13% | Acciones |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | $420 425 | 72 114 | 0,12% | Acciones |
| MERCER GLOBAL ADVISORS INC /ADV | $416 579 | 72 956 | 0,12% | Acciones |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $401 567 | 89 237 | 0,12% | Acciones |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $396 932 | 69 515 | 0,11% | Acciones |
| OSAIC HOLDINGS, INC. | $373 171 | 65 354 | 0,11% | Acciones |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $361 906 | 63 381 | 0,10% | Acciones |
| Quantinno Capital Management LP | $340 122 | 59 566 | 0,10% | Acciones |
| UMB Bank, n.a. | $325 470 | 57 000 | 0,09% | Acciones |
| CWM, LLC | $320 189 | 71 153 | 0,09% | Acciones |
| MetLife Investment Management, LLC | $315 974 | 55 337 | 0,09% | Acciones |
| NewEdge Advisors, LLC | $299 118 | 52 385 | 0,09% | Acciones |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $286 000 | 50 000 | 0,08% | Acciones |
| BARCLAYS PLC | $273 749 | 47 942 | 0,08% | Acciones |
| Russell Investments Group, Ltd. | $272 623 | 47 745 | 0,08% | Acciones |
| TUDOR INVESTMENT CORP ET AL | $255 123 | 44 680 | 0,07% | Acciones |
| Quadrature Capital Ltd | $252 182 | 44 165 | 0,07% | Acciones |
| PROFUND ADVISORS LLC | $243 743 | 42 687 | 0,07% | Acciones |
| EntryPoint Capital, LLC | $227 469 | 39 837 | 0,07% | Acciones |
| Verdad Advisers, LP | $214 125 | 37 500 | 0,06% | Acciones |
| AXQ CAPITAL, LP | $211 967 | 37 122 | 0,06% | Acciones |
| Balyasny Asset Management L.P. | $210 471 | 36 860 | 0,06% | Acciones |
| AIMZ Investment Advisors, LLC | $205 903 | 36 060 | 0,06% | Acciones |
| Invesco Ltd. | $205 748 | 36 033 | 0,06% | Acciones |
| CITADEL ADVISORS LLC | $184 433 | 32 300 | 0,05% | Opción de compra |
| JANUS HENDERSON GROUP PLC | $177 611 | 39 469 | 0,05% | Acciones |
| UBS Group AG | $172 573 | 30 223 | 0,05% | Acciones |
| Graham Capital Management, L.P. | $164 471 | 28 804 | 0,05% | Acciones |
| Nuveen, LLC | $158 892 | 27 827 | 0,05% | Acciones |
| NEW YORK STATE COMMON RETIREMENT FUND | $157 253 | 27 540 | 0,05% | Acciones |
| WOLVERINE TRADING, LLC | $144 700 | 20 000 | 0,04% | Opción de compra |
| Arax Advisory Partners | $144 292 | 25 270 | 0,04% | Acciones |
| CAPTRUST FINANCIAL ADVISORS | $144 240 | 25 261 | 0,04% | Acciones |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $143 646 | 25 157 | 0,04% | Acciones |
| Police & Firemen's Retirement System of New Jersey | $143 601 | 25 149 | 0,04% | Acciones |
| IEQ CAPITAL, LLC | $137 040 | 24 000 | 0,04% | Acciones |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $131 655 | 23 057 | 0,04% | Acciones |
| Aigen Investment Management, LP | $131 016 | 22 945 | 0,04% | Acciones |
Informantes de la empresa 40 insiders · 15 directivos · 16 consejeros
| Insider | Rol | Última actividad | Acciones en propiedad | Compras 12m | Ventas 12m | Neto 12m |
|---|---|---|---|---|---|---|
| Samraat S. Raha | President and CEO | 11 de junio de 2026 A | 1 068 083 | 0 | 0 | $0 |
| Paul J Diaz | President and CEO | 24 de marzo de 2022 F | 1 159 429 | 0 | 0 | $0 |
| Jay M Moyes | Chief Financial Officer | 15 de octubre de 2007 M | 25 282 | 0 | 0 | $0 |
| Peter D Meldrum | President & C.E.O. | 6 de mayo de 2015 M | 10 424 | 0 | 0 | $0 |
| Craig T Benson | President, Myriad RBM | 17 de septiembre de 2013 A | — | 0 | 0 | $0 |
| Gregory C Critchfield | President Myriad Genetic Labs | 15 de septiembre de 2009 A | 129 546 | 0 | 0 | $0 |
| Brian J Donnelly | Chief Commerical Officer | 11 de junio de 2026 A | 573 363 | 0 | 0 | $0 |
| Raj Jampa | Chief Technology Officer | 1 de junio de 2026 A | 251 889 | 0 | 0 | $0 |
| Jerry S Lanchbury | Chief Scientific Officer | 9 de octubre de 2021 F | 264 324 | 0 | 0 | $0 |
| Gary A. King | Exec. VP International Ops | 30 de septiembre de 2019 D | 148 397 | 0 | 0 | $0 |
| Richard M Marsh | E.V.P., General Counsel | 30 de septiembre de 2018 D | 144 174 | 0 | 0 | $0 |
| Mark H Skolnick | Chief Scientific Officer | 5 de noviembre de 2009 M | 34 000 | 0 | 0 | $0 |
| Adrian N Hobden | Pres. Myriad Pharmaceuticals | 8 de junio de 2009 M | 234 071 | 0 | 0 | $0 |
| William A Hockett III | V. P. of Corp Communications | 10 de septiembre de 2008 A | 9 001 | 0 | 0 | $0 |
| George S Simon | V.P. Business Development | 12 de enero de 2007 M | 2 278 | 0 | 0 | $0 |
| Rashmi Kumar | Consejero | 8 de junio de 2026 S | 171 889 | 0 | 1 | $-66 843 |
| Mark Steven Davis | Consejero | 4 de junio de 2026 A | 106 665 | 0 | 0 | $0 |
| Lee Nisley Newcomer | Consejero | 4 de junio de 2026 A | 191 842 | 0 | 0 | $0 |
| Daniel Skovronsky | Consejero | 4 de junio de 2026 A | 195 507 | 0 | 0 | $0 |
| Colleen F Reitan | Consejero | 4 de junio de 2026 A | 152 030 | 0 | 0 | $0 |
| Louise S. Phanstiel | Consejero | 4 de junio de 2026 A | 341 652 | 0 | 0 | $0 |
| Heinrich Dreismann | Consejero | 4 de junio de 2026 A | 231 145 | 0 | 0 | $0 |
| Paul Bisaro | Consejero | 4 de junio de 2026 A | 157 142 | 1 | 0 | $27 600 |
| Lawrence C Best | Consejero | 5 de diciembre de 2019 A | 60 790 | 0 | 0 | $0 |
| Linda S Wilson | Consejero | 7 de enero de 2010 M | 2 500 | 0 | 0 | $0 |
| Dale A Stringfellow | Consejero | 17 de febrero de 2005 A | — | 0 | 0 | $0 |
| Arthur H Hayes JR | Consejero | 12 de noviembre de 2003 A | — | 0 | 0 | $0 |
| MYRIAD GENETICS INC | Propietario del 10% | 17 de junio de 2009 J | 0 | 0 | 0 | $0 |
| Benjamin Richard Wheeler | — | 16 de agosto de 2026 F | 289 748 | 0 | 0 | $0 |
| Daniel K Spiegelman | — | 4 de junio de 2024 S | 32 917 | 0 | 0 | $0 |
| Dennis Langer | — | 3 de agosto de 2021 M | 89 527 | 0 | 0 | $0 |
| Heinrich Dreismann | — | 3 de junio de 2021 A | 83 527 | 0 | 0 | $0 |
| Walter Gilbert PHD | — | 13 de diciembre de 2019 P | 54 150 | 0 | 0 | $0 |
| John T Henderson | — | 5 de diciembre de 2019 A | 76 040 | 0 | 0 | $0 |
| Mark Christopher Capone | — | 30 de septiembre de 2019 D | 522 216 | 0 | 0 | $0 |
| Walter Lloyd Sanders | — | 30 de septiembre de 2018 D | 36 195 | 0 | 0 | $0 |
| James S Evans | — | 30 de septiembre de 2014 M | 48 128 | 0 | 0 | $0 |
| Wayne W Laslie | — | 8 de mayo de 2009 M | 44 260 | 0 | 0 | $0 |
| Robert S Attiyeh | — | 13 de noviembre de 2008 A | 3 000 | 0 | 0 | $0 |
| Arthur Hull Hayes JR | — | 15 de noviembre de 2007 A | 0 | 0 | 0 | $0 |
Informantes de las presentaciones SEC Form 3/4/5; neto = solo P/S de mercado abierto
Propiedad de ETFs Mantenido por 41 ETFs
El peso refleja solo las tenencias directas de acciones (N-PORT); los fondos apalancados o basados en derivados pueden tener exposición adicional a swaps no mostrada.
| Fondo | Ponderación | Unidades | A fecha de | Fuente |
|---|---|---|---|---|
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,41% | 28 166 SH | 8 de agosto de 2026 | Diario |
| GNOM · Global X Funds | 0,35% | 48 961 NS | 31 de mayo de 2026 | N-PORT |
| FSCC · Federated Hermes ETF Trust | 0,30% | 211 853 NS | 31 de mayo de 2026 | N-PORT |
| HAPS · Harbor ETF Trust | 0,27% | 88 226 NS | 30 de abril de 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,12% | 125 944 NS | 30 de abril de 2026 | N-PORT |
| VFMF · VANGUARD WELLINGTON FUND | 0,10% | 117 614 SH | 8 de agosto de 2026 | Diario |
| VFQY · VANGUARD WELLINGTON FUND | 0,08% | 62 341 SH | 8 de agosto de 2026 | Diario |
| VFVA · VANGUARD WELLINGTON FUND | 0,06% | 86 916 SH | 8 de agosto de 2026 | Diario |
| GSSC · Goldman Sachs ETF Trust | 0,05% | 130 295 NS | 31 de mayo de 2026 | N-PORT |
| NUSC · Nushares ETF Trust | 0,04% | 100 214 NS | 30 de abril de 2026 | N-PORT |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,03% | 80 572 SH | 8 de agosto de 2026 | Diario |
| FNDA · SCHWAB STRATEGIC TRUST | 0,02% | 492 881 NS | 31 de mayo de 2026 | N-PORT |
| IBB · iShares Trust | 0,02% | 644 761 SH | 8 de agosto de 2026 | Diario |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,02% | 532 111 SH | 8 de agosto de 2026 | Diario |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,02% | 174 375 SH | 8 de agosto de 2026 | Diario |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,02% | 17 119 SH | 8 de agosto de 2026 | Diario |
| IWN · iShares Trust | 0,02% | 851 327 SH | 8 de agosto de 2026 | Diario |
| SMLF · iShares Trust | 0,01% | 184 988 SH | 8 de agosto de 2026 | Diario |
| JPSE · J.P. Morgan Exchange-Traded Fund Tr… | 0,01% | 17 035 NS | 30 de abril de 2026 | N-PORT |
| RSSL · Global X Funds | 0,01% | 40 139 NS | 30 de abril de 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,01% | 1 108 712 SH | 8 de agosto de 2026 | Diario |
| VHT · VANGUARD WORLD FUND | 0,01% | 270 010 SH | 8 de agosto de 2026 | Diario |
| AVSC · AMERICAN CENTURY ETF TRUST | 0,01% | 68 802 NS | 31 de mayo de 2026 | N-PORT |
| IWM · iShares Trust | 0,01% | 2 367 016 SH | 8 de agosto de 2026 | Diario |
| DFAS · Dimensional ETF Trust | 0,01% | 275 229 NS | 30 de abril de 2026 | N-PORT |
| ITWO · ProShares Trust | 0,01% | 4 334 NS | 31 de mayo de 2026 | N-PORT |
| SCHA · SCHWAB STRATEGIC TRUST | 0,01% | 443 693 NS | 31 de mayo de 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,01% | 41 272 NS | 30 de abril de 2026 | N-PORT |
| UWM · ProShares Trust | 0,01% | 3 389 NS | 31 de mayo de 2026 | N-PORT |
| URTY · ProShares Trust | 0,00% | 3 427 NS | 31 de mayo de 2026 | N-PORT |
| TILT · FlexShares Trust | 0,00% | 8 932 NS | 30 de abril de 2026 | N-PORT |
| FNDB · SCHWAB STRATEGIC TRUST | 0,00% | 6 352 NS | 31 de mayo de 2026 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,00% | 3 176 NS | 31 de mayo de 2026 | N-PORT |
| HDG · ProShares Trust | 0,00% | 86 NS | 31 de mayo de 2026 | N-PORT |
| SCHB · SCHWAB STRATEGIC TRUST | 0,00% | 54 235 NS | 31 de mayo de 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 125 607 SH | 8 de agosto de 2026 | Diario |
| IWV · iShares Trust | 0,00% | 23 126 SH | 8 de agosto de 2026 | Diario |
| AVUS · AMERICAN CENTURY ETF TRUST | 0,00% | 2 500 NS | 31 de mayo de 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 2 881 677 SH | 8 de agosto de 2026 | Diario |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 7 148 SH | 8 de agosto de 2026 | Diario |
| AVSU · AMERICAN CENTURY ETF TRUST | 0,00% | 3 NS | 31 de mayo de 2026 | N-PORT |